Clinical Trials · NCT07619495
Injectable Semaglutide vs Dulaglutide in Individuals at Cardiovascular Risk
- Phase
- N/A
- Recruitment status
- Completed
- Sponsor
- Brigham and Women's Hospital
- Enrollment
- 120,000
- Start date
- Jan 2026
- Locations
- 1 site, United States
- Primary endpoint
- Composite of all-cause mortality, myocardial infarction, or stroke.